Michael Marcus, MD
Child & Adolescent Psychiatry · Boston, MANPI 1669571253
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 288 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Sunovion Pharmaceuticals Inc. at 28.1% of the total. Reporting peaked in 2019 at $2,259 and has fallen 99.1% since, to $21 in 2025. Among child & adolescent psychiatry clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 288 payments — averaging $14.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$1K
- Takeda Pharmaceuticals U.S.A., Inc.$917
- AbbVie$460
- Otsuka America Pharmaceutical, Inc.$455
- Johnson & Johnson$203
- Shire North American Group Inc$151
- plus $740 from 10 others
What the payments were for
- Food & beverage$3,99498%
- Education$772%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 70 | $1,145 |
| Takeda Pharmaceuticals U.S.A., Inc. | 80 | $917 |
| AbbVie(2 entities) | 34 | $460 |
| Otsuka America Pharmaceutical, Inc. | 32 | $455 |
| Johnson & Johnson | 15 | $203 |
| Shire North American Group Inc | 13 | $151 |
| Lundbeck LLC | 9 | $125 |
| Neurocrine Biosciences, Inc. | 6 | $116 |
| Ironshore Pharmaceuticals Inc. | 6 | $104 |
| Avanir Pharmaceuticals, Inc. | 6 | $98 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $96 |
| Indivior Inc. | 4 | $62 |
| Neos Therapeutics, LP | 4 | $55 |
| Corium, LLC | 4 | $45 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
How this compares
$4,071 in reported general payments places this provider in the 90th percentile of 104 child & adolescent psychiatry providers in Massachusetts.
See all child & adolescent psychiatry providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 31 | $44,406 |
| Aripiprazole | 78 | $18,579 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 129 | $14,271 |
| TrintellixVortioxetine Hydrobromide | 22 | $10,928 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 227 | $7,859 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 43 | $2,963 |
| Bupropion XlBupropion Hcl | 198 | $2,578 |
| Alprazolam | 304 | $2,362 |
| Clonazepam | 311 | $2,274 |
| Methylphenidate Hcl | 89 | $1,964 |
| Methylphenidate ErMethylphenidate Hcl | 27 | $1,855 |
| Escitalopram Oxalate | 142 | $1,717 |
| Ziprasidone Hcl | 32 | $1,585 |
| Lorazepam | 280 | $1,544 |
| Olanzapine | 52 | $1,339 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $455 | $44,40631 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $917 | $10,92822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 104 child & adolescent psychiatry providers in Massachusetts.
Other child & adolescent psychiatry in Boston
- David DemasoBoston$41K
- Matthew SiegelBoston$11K
- Janet WozniakBoston$8K
- Joseph Gonzalez HeydrichBoston$7K
- Ranna ParekhBoston$3K
- Joseph BiedermanBoston$3K
- Ireen AhmedBoston$3K
- Annah AbramsBoston$3K
- Yoshio KanekoBoston$2K
- Kyle WilliamsBoston$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.